Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Our systematic review found that GLP-1 RAs (such as exenatide, liraglutide, semaglutide, and the dual agonist tirzepatide) may significantly improve multiple facets of IIH: headaches, visual function, and induce substantial weight loss
Bacterial growth is subtly altering the pH and degrading the peptide
Taking GLP-1s appears to alter these areas and change the levels of reward-related neurotransmitters dopamine and glutamate, a review of related studies suggests
Weight of evidence: Overall evidence is Low-Moderate: multiple animal studies and a growing number of small clinical trials suggest benefits across gutbrain signaling, social and behavioral domains, gastrointestinal symptoms, and neurophysiological patterns, yet most human studies rely on caregiver-reported outcomes, lack biomarker integration, and seldom control for diet, comorbidities, or baseline microbiome composition
While oral supplements are effective, absorption can be influenced by timing and digestive health
